Literature DB >> 25420451

Pathological and protective immunity to Pneumocystis infection.

Taylor Eddens1, Jay K Kolls.   

Abstract

Pneumocystis jirovecii is a common opportunistic infection in the HIV-positive population and is re-emerging as a growing clinical concern in the HIV-negative immunosuppressed population. Newer targeted immunosuppressive therapies and the discovery of rare genetic mutations have furthered our understanding of the immunity required to clear Pneumocystis infection. The immune system can also mount a pathologic response against Pneumocystis following removal of immunosuppression and result in severe damage to the host lung. The current review will examine the most recent epidemiologic studies about the incidence of Pneumocystis in the HIV-positive and HIV-negative populations in the developing and developed world and will detail methods of diagnosis for Pneumocystis pneumonia. Finally, this review aims to summarize the known mediators of immunity to Pneumocystis and detail the pathologic immune response leading to Pneumocystis-related immune reconstitution inflammatory syndrome.

Entities:  

Mesh:

Year:  2014        PMID: 25420451      PMCID: PMC4329019          DOI: 10.1007/s00281-014-0459-z

Source DB:  PubMed          Journal:  Semin Immunopathol        ISSN: 1863-2297            Impact factor:   9.623


  100 in total

Review 1.  Pneumocystis: unraveling the cloak of obscurity.

Authors:  Melanie T Cushion
Journal:  Trends Microbiol       Date:  2004-05       Impact factor: 17.079

Review 2.  Pneumocystis pneumonia.

Authors:  Charles F Thomas; Andrew H Limper
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

3.  Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Elliott L Crow; Samir P Bhagwat; Terry W Wright
Journal:  Infect Immun       Date:  2006-08-28       Impact factor: 3.441

4.  Pneumocystis pneumonia--a retrospective study 1991-2001 in Gothenburg, Sweden.

Authors:  Laila Mikaelsson; Gunnar Jacobsson; Rune Andersson
Journal:  J Infect       Date:  2006-01-03       Impact factor: 6.072

5.  Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia.

Authors:  T W Wright; R H Notter; Z Wang; A G Harmsen; F Gigliotti
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection.

Authors:  Frances E Lund; Melissa Hollifield; Kevin Schuer; J Louise Lines; Troy D Randall; Beth A Garvy
Journal:  J Immunol       Date:  2006-05-15       Impact factor: 5.422

Review 7.  Pneumocystis jirovecii pneumonia in kidney transplantation.

Authors:  N Goto; S Oka
Journal:  Transpl Infect Dis       Date:  2011-10-31       Impact factor: 2.228

8.  Immune reconstitution during Pneumocystis lung infection: disruption of surfactant component expression and function by S-nitrosylation.

Authors:  Elena N Atochina-Vasserman; Andrew J Gow; Helen Abramova; Chang-Jiang Guo; Yaniv Tomer; Angela M Preston; James M Beck; Michael F Beers
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

9.  Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.

Authors:  Cristina Mussini; Christian Manzardo; Margaret Johnson; Antonella d'Arminio Monforte; Caterina Uberti-Foppa; Andrea Antinori; M John Gill; Laura Sighinolfi; Vanni Borghi; Adriano Lazzarin; José M Miró; Caroline Sabin
Journal:  AIDS       Date:  2008-11-30       Impact factor: 4.177

Review 10.  Current epidemiology of Pneumocystis pneumonia.

Authors:  Alison Morris; Jens D Lundgren; Henry Masur; Peter D Walzer; Debra L Hanson; Toni Frederick; Laurence Huang; Charles B Beard; Jonathan E Kaplan
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more
  17 in total

1.  Characterization of Pneumocystis jirovecii pneumonia at three tertiary comprehensive hospitals in southern China.

Authors:  Yan-Hui Chen; Xue-Yao Fang; Yue-Ting Li; Yan-Ling Liu; Ya-Ping Hang; Yan-Ping Xiao; Xing-Wei Cao; Qiao-Shi Zhong; Long-Hua Hu
Journal:  Braz J Microbiol       Date:  2020-05-03       Impact factor: 2.476

2.  Eosinophils Contribute to Early Clearance of Pneumocystis murina Infection.

Authors:  Taylor Eddens; Waleed Elsegeiny; Michael P Nelson; William Horne; Brian T Campfield; Chad Steele; Jay K Kolls
Journal:  J Immunol       Date:  2015-05-20       Impact factor: 5.422

3.  Murine models of Pneumocystis infection recapitulate human primary immune disorders.

Authors:  Waleed Elsegeiny; Mingquan Zheng; Taylor Eddens; Richard L Gallo; Guixiang Dai; Giraldina Trevejo-Nunez; Patricia Castillo; Kara Kracinovsky; Hillary Cleveland; William Horne; Jonathan Franks; Derek Pociask; Mark Pilarski; John F Alcorn; Kong Chen; Jay K Kolls
Journal:  JCI Insight       Date:  2018-06-21

4.  Pneumocystis-Driven Inducible Bronchus-Associated Lymphoid Tissue Formation Requires Th2 and Th17 Immunity.

Authors:  Taylor Eddens; Waleed Elsegeiny; Maria de la Luz Garcia-Hernadez; Patricia Castillo; Giraldina Trevejo-Nunez; Katelin Serody; Brian T Campfield; Shabaana A Khader; Kong Chen; Javier Rangel-Moreno; Jay K Kolls
Journal:  Cell Rep       Date:  2017-03-28       Impact factor: 9.423

5.  Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control.

Authors:  Edurne Arriola; Matthew Wheater; Radhika Krishnan; James Smart; Vipul Foria; Christian Ottensmeier
Journal:  Oncoimmunology       Date:  2015-05-27       Impact factor: 8.110

6.  A Novel CD4+ T Cell-Dependent Murine Model of Pneumocystis-driven Asthma-like Pathology.

Authors:  Taylor Eddens; Brian T Campfield; Katelin Serody; Michelle L Manni; William Horne; Waleed Elsegeiny; Kevin J McHugh; Derek Pociask; Kong Chen; Mingquan Zheng; John F Alcorn; Sally Wenzel; Jay K Kolls
Journal:  Am J Respir Crit Care Med       Date:  2016-10-01       Impact factor: 21.405

7.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

Authors:  Georgios Chamilos; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

Review 8.  Immune reconstitution inflammatory syndrome associated with pulmonary pathogens.

Authors:  Radha Gopal; Rekha R Rapaka; Jay K Kolls
Journal:  Eur Respir Rev       Date:  2017-01-03

9.  A protracted course of Pneumocystis pneumonia in the setting of an immunosuppressed child with GMS-negative bronchoalveolar lavage.

Authors:  Taylor Eddens; Eunkyung Song; Monica I Ardura; Jay K Kolls
Journal:  Med Mycol Case Rep       Date:  2016-04-25

Review 10.  Nonhuman Primate Models of Respiratory Disease: Past, Present, and Future.

Authors:  Lisa A Miller; Christopher M Royer; Kent E Pinkerton; Edward S Schelegle
Journal:  ILAR J       Date:  2017-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.